Advancing Cancer Care Through Research – Alexander I. Spira MD, PhD, FACP, FASCO
Watch Alex Spira, MD, PhD, FACP, FASCO discuss findings from a global Phase I study evaluating an investigational therapy for previously treated patients with EGFR-mutated non-small cell lung cancer, presented at the IASLC World Conference on Lung Cancer. Link — Metastatic EGFR-Mutated NSCLC Global Study of Izalontamab Brenitecan – The ASCO Post
Virginia Cancer Specialists Clinical Research Leader Receives SCRI Site Partnership Excellence Award
FAIRFAX, Va., August 4, 2026 /PRNewswire/ — Virginia Cancer Specialists, a premier oncology practice in Northern Virginia and a leader in community-based cancer research, is proud to announce that Marcy Sullivan RN, BSN, OCN, Director of Research Operations at Virginia Cancer Specialists Research Institute, has been recognized with the Sarah Cannon Research Institute (SCRI) Site Partnership […]
Virginia Cancer Specialists Announces 21 Physicians Named to Washingtonian “Top Doctors” Hall of Fame
FAIRFAX, Va., June 17, 2026 /PRNewswire/ — Virginia Cancer Specialists is proud to announce that 21 of its physicians have been named to the Washingtonian “Top Doctors” Hall of Fame—an honor reserved for an elite group of physicians who have been consistently recognized by their peers as among the region’s best. This distinction reflects years […]
Breakthrough Targeted Therapy Shows Promise for KRAS-Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role
FOR IMMEDIATE RELEASE Breakthrough Targeted Therapy Shows Promise for KRAS-Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role Fairfax, VA — May 12, 2026 — Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first-in-class targeted oral therapy for patients […]
Advancing Sarcoma Surgery: A Surgeon’s Perspective – Felasfa M. Wodajo, MD
July marks Sarcoma Awareness Month, a time to spotlight this rare group of cancers and the ongoing efforts to improve the lives of those affected. As a musculoskeletal tumor surgeon, I see firsthand how surgical innovation continues to shape the future of sarcoma care. These advances are improving outcomes, preserving function, and offering patients more […]
FDA Approves New Shield Blood Test for Colorectal Cancer Screening: What You Need to Know, Keeran Sampat, MD
The FDA has approved a new blood test for colorectal cancer named Shield, developed by Guardant Health. This test, which requires only a blood sample, detects early-stage cancers and some polyps by identifying DNA fragments shed by cancer cells. Shield is designed for individuals aged 45 and older who are at average risk for colon […]
New Treatment Breakthrough: Amivantamab Plus Lazertinib for Advanced Lung Cancer – Timothy A. McCarthy, MD
A groundbreaking study published in June 2024 in The New England Journal of Medicine has introduced a promising new treatment for a specific type of advanced lung cancer. The research, co-authored by Alex Spira, MD, PhD, FACP, FACSO, Medical Oncologist and Co-Director of The Virginia Cancer Specialists Research Institute, highlights the combination of two drugs, […]
Dr. Mitul Gandhi, Medical Oncologist at Virginia Cancer Specialists, Co-Authors Real-World Study Assessing Efficacy of Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndromes
Dr. Mitul Gandhi, Medical Oncologist at Virginia Cancer Specialists, Co-Authors Real-World Study Assessing Efficacy of Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndromes This study highlights the need for new therapies that improve complete remission and survival rates in patients with HR-MDS. Fairfax, Virginia, February 9, 2024 – Virginia Cancer Specialists, a premier provider of […]
Brentuximab Vedotin: A Promising Frontline Therapy for Older Hodgkin Lymphoma Patients
A recent study published by Dr. Dipti Patel-Donnelly, of Virginia Cancer Specialists and colleagues has shed light on a groundbreaking approach in the treatment of advanced-stage classical Hodgkin lymphoma (cHL) in older patients. This noncomparative phase 2 study, detailed in the research article here, explores the efficacy of brentuximab vedotin (BV) in combination with dacarbazine […]